Home » Treatment and Research » Medication Overview

Medication Overview

Need new introductory text here…

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nulla vitae laoreet est. Duis interdum laoreet massa, at blandit libero cursus at. In est magna, porta quis massa vitae, tincidunt venenatis ligula.

Action items for Medication Overview

Visit these 3 links for in-depth information and articles

Action item one

Action item two

Action item three

For a deeper dive into this topic you’ll find additional information here.

FEATURE

TBD - will add after article migration

ADDITIONAL READING

April 8, 2022

ASH 2021: Dr. Constantine Tam on Zanubrutinib in Combination with Venetoclax for Patients with Deletion 17p

CLL and SLL patients with deletion 17p do not respond well to chemoimmunotherapy. But new targeted therapies may help. Zanubrutinib is a next-generation BTK inhibitor being tested in combination with venetoclax for treating patients with deletion 17p. Results from a Phase III trial of this combination were presented at

March 30, 2022

ASH 2021: Dr. Bill Wierda Discusses Outcomes of Adding Oral Venetoclax (Ven) to Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Currently Receiving Oral Ibrutinib (Ibr).

At the annual meeting of the American Society of Hematology (ASH) 2021, Dr. Mathew Davids from the Dana-Farber Cancer Institute in Boston interviews Dr. Bill Wierda from the MD Anderson Cancer Center in Houston. They discuss the benefits of combined finite therapy to achieve U-MRD with a

March 16, 2022

A CLL Trial in Progress for Those Who Relapsed After Venetoclax Plus Obinutuzumab

Here we review ReVenG, a phase 2 study of venetoclax plus obinutuzumab retreatment (“second time”) in patients with relapsed chronic lymphocytic leukemia (CLL) (ClinicalTrials.gov Identifier: NCT04895436) that fits that category. It was presented at ASH 2021 by Dr. Matthew Davids.

February 24, 2022

ASH 2021: BRUIN CLL-321: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Investigator’s Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)

Dr. Jeff Sharman and colleagues presented this research at the American Society for Hematology annual meeting held December 2021 (ASH 2021).

February 23, 2022

Clinical Trials: Frequently Asked Questions (FAQ)

Considering a clinical trial may seem like a daunting prospect, but sometimes it can be the smartest strategy. Here are some basic questions to help you make a good decision. 1. What is a clinical trial? The search for new and better treatments for chronic lymphocytic leukemia/small lymphocytic lymphoma

February 23, 2022

BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia

This should be good news for CLL/SLL patients. If things go as planned, we could have FDA approval of a third irreversibly binding BTK inhibitor, zanubrutinib, before the end of the year.

Treatment and Research

Relapsed/Refractory or Later Therapies

MRD and Disease Monitoring

RECENT NEWS

When appropriate, the CLL Society will be posting updates and background information on the present Coronavirus pandemic focusing on reliable primary sources of information and avoiding most of the news that is not directly from reliable medical experts or government and world health agencies.

ASH 2021: Dr. Jennifer Woyach with an Update on Ibrutinib vs. Chemoimmunotherapy as a Frontline Treatment for Chronic Lymphocytic Leukemia

An Immunologist Reviews CLL/SLL Patients and Their Compromised Immunity

Application of National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for CLL/SLL from the informCLL Real-World Registry

ASH 2021: Age-Related Differences in the Informational Experiences and Needs of Patients with Lymphoma: Results from the 2020 Lymphoma Coalition Global Patient Survey